顶部联系方式

Time of issue:2018-03-12 00:00:00

Have Any Questions?  Mabspace BiosciencesInfo@mabspacebio.com 迈博斯生物0512-86861701

搜索
迈博斯生物

语言切换

Time of issue:2019-11-21 00:00:00
这是描述信息

NEWS

>>
>>
Cancer Immunotherapy Forum and Maibos Bio's 5th Anniversary Ceremony Completed Successfully

Cancer Immunotherapy Forum and Maibos Bio's 5th Anniversary Ceremony Completed Successfully

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2019-11-28 14:54
  • Views:

(Summary description)On May 9, 2018, Maibos Bio celebrated its fifth anniversary. On the same day, the company announced that it had completed a Series B USD 40 million financing and the official operation of ...

Cancer Immunotherapy Forum and Maibos Bio's 5th Anniversary Ceremony Completed Successfully

(Summary description)On May 9, 2018, Maibos Bio celebrated its fifth anniversary. On the same day, the company announced that it had completed a Series B USD 40 million financing and the official operation of ...

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2019-11-28 14:54
  • Views:
Information

On May 9, 2018, Maibos Bio celebrated its fifth anniversary. On the same day, the company announced that it had completed a Series B USD 40 million financing and the official operation of the innovative antibody drug R & D center.

 

The fifth anniversary celebration first began in an academic feast. The tumor immunotherapy forum hosted by Maibos Bio was held at Four Points by Sheraton Suzhou. The forum invited the domestic biomedical industry, especially many well-known scientists in the field of tumor immunity More than 100 clinical experts, entrepreneurs, investors, and government leaders participated.

 

Firstly, Associate Professor Ji Dongmei of Fudan University Cancer Hospital published his many-year experience summary on the first-phase clinical research of anti-tumor drugs. She started from the determination of the starting dose of the drug, climbing design, selection of enrolled patients, PK design, adjustment of drug delivery mode, laboratory inspection and special inspection, toxicity judgment and efficacy judgment, and explained the clinical trial institute. Follow the general guidelines and how to handle special situations. In the course of explaining, Professor Ji shared from time to time many situations she encountered in actual research, and explained many details in clinical trials with practical cases. Professor Ji believes that the development of tumor therapy will continue to be rapid in the future, and the design of clinical trials for tumor therapy will continue to develop and innovate accordingly.

 

The second part of the forum was a forum discussion on the theme of "Prospects and Strategies for Combined Use in Tumor Immunotherapy". The forum was hosted by Wan Yuntao, head of clinical development and operations of Maibos Bio. The guests who participated in the discussion were: Associate Professor Ji Dongmei of Fudan University Cancer Hospital, Professor Shen Lin, Associate Dean of Peking University Cancer Hospital, and Zhu Rongping, President of R & D of Sansheng Pharmaceutical Group Dr. Wang Zaiqi, head of Roche Shanghai Innovation Center, Dr. Xu Ting, Chairman of Suzhou Corning Jerry Biotechnology Co., Ltd., and Dr. Guo Tong, Vice President of Business Development of IQVIA Greater China.

 

Dr. Wang Zaiqi believes that the effect of the combined use of immune checkpoint inhibitor drugs and traditional tumor treatment methods has not yet made people very satisfied, and there is still much room for improvement. Therefore, tumor immunotherapy and immune checkpoint suppression There are still many opportunities for drug combinations. Dr. Xu Ting believes that as the success and failure of clinical trials continue to accumulate, people's understanding of combined drugs will become more and more rational, and more and more rational drug combinations will be selected based on biological mechanisms and clinical trial development experience. As a statistical expert, Dr. Guo Tong emphasized the rationality of the design of clinical trials of combined drugs from the perspective of collection and processing of trial data. Dr. Zheping Zhu believes that many of the current combined drugs based on PD-1 / PD-L1 antibodies are good for patients, but he should also pay attention to avoid irrational research and development. For the combined use of lymphoma, associate professor Ji Dongmei talked about the basic principles of selecting drugs for combination, including the control of toxic and side effects, and the effects of treatment cannot be offset. Finally, Dean Shen Lin talked about the particularity of digestive system tumors for tumor immunotherapy, reminding everyone not to take the risk, to study the mechanism of the tumor in detail, and to screen patients reasonably, which is expected to improve the success rate of immunotherapy. The forum ended with a lively discussion between experts on stage and audience.

 

Immediately afterwards, a group came to BioBAY where Maibosi Biological R & D Center is located, and the grand opening ceremony of the innovative antibody drug R & D center was held downstairs B6. The chairman and CEO of the company, Dr. Qian Xueming, first gave a welcome speech. He said with deep feeling that the company was established in BioBAY five years ago. It started from a small laboratory of 300 square meters and has been subject to the park during the development process. The government, investment community and peers have supported and helped establish their own innovative antibody drug research and development platform. Now the first PD-L1 product has been successfully launched in the US clinically, and 12 product lines will continue to be pushed forward. The just-rounded B round of financing has also been highly recognized by investment institutions such as Sequoia Capital for Maibos Bio. He thanked the park government and BioBAY for the talented support of Maibos Bio, and thanks to Eli Lilly Asia Fund. Hope The Maibos family will make persistent efforts to promote the company's product research and development, welcome the next five years of glory, and strive to build Maibos Bio into an internationally renowned biopharmaceutical company. Afterwards, Professor Shen Lin also delivered a speech on behalf of the guests, and expressed good wishes to Maibos Bio. Professor Shen said that she had been impressed by his dedication and stubbornness as a scientist when she first met Dr. Qian Xueming. Our country needs such scientists to contribute to the country's medical innovation and the country's oncology drug research and development. She has witnessed the founding and growth of Maibos Pharmaceuticals, and is happy for their persistence and achievements. She hopes that Maibos will have more products to treat patients in the future, so that doctors have more treatment options, and patients have more expectations.

 

Subsequently, Ding Lixin, deputy director of the Suzhou Industrial Park Management Committee, congratulated Maibos Bio for its development achievements in the past five years. In his speech, he said that after 24 years of development and construction, the Suzhou Industrial Park has become one of China's fastest-growing, highest-tech, and most comprehensive development zones. The park will, as always, implement the "pro-business" concept and create a high-quality service environment for high-tech enterprises settled here. In the future, the park will further support the development of Maibos, and hope that the company will soon become a well-known pharmaceutical company with international competitiveness.

 

Finally, Mr. Ding Lixin, Deputy Director of the Suzhou Industrial Park Management Committee, Ms. Xiao Shitao, Deputy Director of the Science and Technology Bureau of Suzhou Industrial Park, Mr. Pang Junyong, President of Suzhou Industrial Park Biological Industry Development Co., Ltd., and Qian Xueming, Chairman and CEO of Maibos Bio The doctor cut the ribbon for the celebration. At the end of the celebration ceremony, Director Ding Lixin and Dr. Qian Xueming unveiled the Maibos Bioinnovative Antibody Drug R & D Center.

Scan the QR code to read on your phone

页脚关于我们

Time of issue:2019-11-23 00:00:00

页脚管道

Time of issue:2019-11-23 00:00:00

页脚新闻

Time of issue:2019-11-23 00:00:00

页脚人力资源

Time of issue:2019-11-23 00:00:00

页脚联系方式

Time of issue:2019-11-23 00:00:00

页脚版权

Time of issue:2019-11-23 00:00:00

Copyright © 2019 Mabspace Biosciences All rights reserved

页脚备案

Time of issue:2019-11-23 00:00:00